



This is an official CDC Health Advisory

Distributed via Health Alert Network January 17, 2013, 10:45AM 10275-CHA-01-17-2013-FLU

Notice to Clinicians: Summary of CDC Recommendations for Influenza Antiviral Medications

CDC continues to recommend antiviral medications for treatment of seasonal influenza and annual vaccination as the best tools for prevention.

Evidence from past influenza seasons and the 2009 H1N1 pandemic has shown that treatment with antiviral medications can have clinical and public health benefit in reducing severe outcomes of influenza when initiated as soon as possible after illness onset.

Clinical trials and observational data show that early antiviral treatment may do the following:

- shorten the duration of fever and illness symptoms
- reduce the risk of complications from influenza (e.g., otitis media in young children, pneumonia, respiratory failure) and death
- shorten the duration of hospitalization

Below is a summary of CDC's influenza antiviral recommendations.

Summary of CDC recommendations for influenza antiviral medications for the 2012-2013 season:

Clinical benefit is greatest when antiviral treatment is administered early. When indicated, antiviral treatment should be started as soon as possible after illness onset, ideally within 48 hours of symptom onset. However, antiviral treatment might still be beneficial in patients with severe, complicated, or progressive illness and in hospitalized patients when started after 48 hours of illness onset, as indicated by observational studies.

Antiviral treatment is recommended as early as possible for any patient with confirmed or suspected influenza who

- is hospitalized;
- has severe, complicated, or progressive illness; or
- o is at higher risk for influenza complications. This list includes:
 - children aged younger than 2 years;
 - adults aged 65 years and older;
 - persons with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematological (including sickle cell disease), metabolic disorders (including diabetes mellitus), or neurologic and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury);

- persons with immunosuppression, including that caused by medications or by HIV infection;
- women who are pregnant or postpartum (within 2 weeks after delivery);
- persons aged younger than 19 years who are receiving long-term aspirin therapy;
- American Indians/Alaska Natives;
- persons who are morbidly obese (i.e., body-mass index is equal to or greater than 40); and
- residents of nursing homes and other chronic-care facilities.

Clinical judgment, on the basis of the patient's disease severity and progression, age, underlying medical conditions, likelihood of influenza, and time since onset of symptoms, is important when making antiviral treatment decisions for high-risk outpatients.

Decisions about starting antiviral treatment should not wait for laboratory confirmation of influenza.

While influenza vaccination is the first and best way to prevent influenza, a history of influenza vaccination does not rule out the possibility of influenza virus infection in an ill patient with clinical signs and symptoms compatible with influenza.

Antiviral treatment also can be considered for any previously healthy, symptomatic outpatient not at high risk with confirmed or suspected influenza on the basis of clinical judgment, if treatment can be initiated within 48 hours of illness onset.

For more information:

A full summary of clinical recommendations that includes the sections listed below is available at

http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm:

- Antiviral Medications Recommended for Treatment and Chemoprophylaxis of Influenza
- Summary of Influenza Antiviral Treatment Recommendations
- Diagnostic Testing for Influenza
- Recommended Dosage and Duration of Treatment or Chemoprophylaxis for Influenza Antiviral Medications
- Chemoprophylaxis
- Adverse Events
- Footnotes
- Selected References

CDC communication to health care providers:

- CDC Information for Pharmacists http://www.cdc.gov/flu/professionals/2012-2013-guidance-pharmacists.htm
- CDC Influenza Update for Pediatricians http://www.cdc.gov/flu/professionals/2012-2013-guidance-pediatricians.htm

FDA Announcement Addressing Intermittent Shortages of Oseltamivir Phosphate (Tamiflu ®) for Oral Suspension (6mg/mL 60 mL):

On January 10, 2013, the U.S. Food and Drug Administration (FDA) released information indicating there may currently be intermittent shortages of <u>Oseltamivir Phosphate (Tamiflu®) for Oral Suspension (6mg/mL 60 mL)</u> - used to treat influenza in children - due to increased demand for the drug. This is the pediatric suspension (liquid). Instructions for pharmacists on how to compound an oral suspension from <u>Tamiflu® 75 mg (adult) capsules</u> are available at http://www.tamiflu.com/hcp/resources/hcp_resources_pharmacists.jsp. These instructions provide for an

alternative oral suspension when commercially manufactured oral suspension formulation is not readily available.

In some cases, clinicians may consider substituting a 30 or 45 mg capsule for children (if dose is appropriate) rather than suspension, particularly if there are spot shortages of suspension. These capsules may be opened and mixed with a sweet liquid, such as regular or sugar-free chocolate syrup, if oral suspension is not available. Instructions to share with caregivers are available here: www.cdc.gov/flu/antivirals/mixing tamiflu ga.htm .

At this time, people seeking vaccination may need to call more than one provider to locate vaccine. The flu vaccine locator (http://flushot.healthmap.org/) may be helpful.

¹ Findings from early data indicate the overall effectiveness of the 2012-2013 seasonal influenza vaccine is 62%. The data are published in "Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2013," in the January 11, 2013, Morbidity and Mortality Weekly Report. This estimate is within the range of what is expected during seasons when most circulating influenza viruses characterized by CDC are like the viruses included in the vaccine.

ii On December 21, 2012, the U.S. Food and Drug Administration (FDA) approved the antiviral medication oseltamivir (trade name Tamiflu®) for the treatment of influenza in people aged 2 weeks and older. An FDA press release related to this announcement is available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333205.htm

DHEC contact information for reportable diseases and reporting requirements

Reporting of influenza is consistent with South Carolina Law requiring the reporting of diseases and conditions to your state or local public health department. (State Law # 44-29-10 and Regulation # 61-20) as per the DHEC 2013 List of Reportable Conditions available at: http://www.scdhec.gov/health/disease/reportables.htm

Federal HIPAA legislation allows disclosure of protected health information, without consent of the individual, to public health authorities to collect and receive such information for the purpose of preventing or controlling disease. (HIPAA 45 CFR §164.512).

Regional Public Health Offices – 2013

Mail or call reports to the Epidemiology Office in each Public Health Region.

Region I Anderson, Oconee

220 McGee Road Anderson, SC 29625 Phone: (864) 260-4358 Fax: (864) 260-5623

Nights / Weekends: 1-866-298-4442

Abbeville, Edgefield, Greenwood, Laurens, McCormick, Saluda

1736 S. Main Street Greenwood, SC 29646 Phone: 1-888-218-5475 Fax: (864) 942-3690 Nights / Weekends: 1-800-420-1915

Region 2 Greenville, Pickens

PO Box 2507 200 University Ridge Greenville, SC 29602-2507 Phone: (864) 282-4139 Fax: (864) 282-4373 Nights / Weekends: (864) 809-3825

Cherokee, Spartanburg, Union

PO Box 4217 151 E. Wood Street Spartanburg, SC 29305-4217 Phone: (864) 282-4139 Fax: (864) 282-4373 Nights / Weekends: (864) 809-3825

Region 3

Chester, Lancaster, York
PO Box 817
1833 Pageland Highway
Lancaster, SC 29720
Phone: (803) 286-9948
Fax: (803) 286-5418
Nights / Weekends: 1-866-867-3886

Region 3 (continued)

Fairfield, Lexington, Newberry, Richland

2000 Hampton Street Columbia, SC 29204 Phone: (803) 576-2749 Fax: (803) 576-2993

Nights / Weekends: 1-888-554-9915

Region 4

Chesterfield, Darlington, Dillon, Florence, Marlboro, Marion

145 E. Cheves Street Florence, SC 29506 Phone: (843) 661-4830 Fax: (843) 661-4859 Nights / Weekends: (843) 601-7051

Clarendon, Kershaw, Lee, Sumter

PO Box 1628 105 North Magnolia Street Sumter, SC 29150 Phone: (803) 773-5511 Fax: (803) 775-9941 Nights/Weekends: 803-458-1847

Region 5 Bamberg, Calhoun, Orangeburg

PO Box 1126 1550 Carolina Avenue Orangeburg, SC 29116 Phone: (803) 533-7199 Fax: (803) 533-7134 Nights / Weekends: (803) 535-9265

Aiken, Allendale, Barnwell

222 Beaufort Street, NE Aiken, SC 29801 Phone: (803) 642-1618 Fax: (803) 643-8386 Nights / Weekends: (803) 645-8167 Region 6

Georgetown, Horry, Williamsburg

1931 Industrial Park Road Conway, SC 29526-5482 Phone: (843) 915-8804 Fax: (843) 365-0085

Nights/Weekends: (843) 340-4754

Region 7

Berkeley, Charleston, Dorchester 4050 Bridge View Drive, Suite 600 N. Charleston, SC 29405 Phone: (843) 953-0047 Fax: (843) 953-0051 Nights / Weekends: (843) 219-8470

Region 8

Beaufort, Colleton, Hampton, Jasper

219 S. Lemacks Street Walterboro, SC 29488 Phone: (843) 441-1091 Fax: (843) 549-6845

Nights / Weekends: 1-843-441-1091

<u>DHEC Bureau of Disease Control</u> Division of Acute Disease Epidemiology

1751 Calhoun Street Box 101106 Columbia, SC 29211 Phone: (803) 898-0861 Fax: (803) 898-0897

Nights / Weekends: 1-888-847-0902



www.scdhec.gov

Categories of Health Alert messages:

Health Alert Conveys the highest level of importance; warrants immediate action or attention.

Health Advisory Health UpdateProvides important information for a specific incident or situation; may not require immediate action. Provides updated information regarding an incident or situation; unlikely to require immediate action.